Merck & Co. Inc. is buying Cidara Therapeutics Inc. for $9.2 billion to acquire a late-stage flu candidate and also to outrace blockbuster Keytruda’s looming patent expiration. CD-388, Cidara’s lead ...
Merck & Co. and Bayer’s Verquvo failed to deliver a composite cardiovascular benefit for certain patients with stable heart failure with reduced ejection fraction (HFrEF). The phase 3 Victor trial ...
Merck & Co. is stepping up to the plate to raise awareness of the dangers of high LDL cholesterol and how it can increase the risk of atherosclerotic cardiovascular disease (ASCVD). Joining the New ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results